June 3, 2017 Median overall survival (OS) was 7.4 months longer among patients with platinum-sensitive, relapsed ovarian cancer who were given chemotherapy with cediranib followed by maintenance therapy with cediranib in the ICON6 trial. The cediranib arm was compared with chemotherapy plus placebo. Jonathan A. Ledermann, MD, of the University College London Cancer Institute,...
Pro zobrazení tohoto obsahu je třeba být přihlášen.